CYP2C9 rs1057910 Genotype and Its Association with Paraclinical Characteristics in Gout Patients in the Northeast Region of Vietnam
Abstract
BACKGROUND: Celecoxib and lesinurad are medications used in the management of gout, and their metabolism is significantly influenced by genetic variations in the CYP2C9 enzyme. CYP2C9*3 (rs1057910) is associated with reduced CYP2C9 activity. This study investigated the association between CYP2C9 rs1057910 genotype and paraclinical characteristics in gout patients from the Northeast region of Vietnam.
METHODS: A total of 139 gout patients were recruited and their paraclinical characteristics including red blood cell, hemoglobin, hematocrit, white blood cell, neutrophil, lymphocyte, platelet, glucose, urea, creatinine, uric acid, triglyceride, total cholesterol, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were collected. The CYP2C9 rs1057910 genotypes were identified by Sanger sequencing method of PCR products, analyzed with BioEdit software, and verified using the NCBI dbVar database. Statistical analyses were performed using SPSS.
RESULTS: The cohort was predominantly male (93.5%), with female patients showing a significantly higher mean age (70.33±10.64 years) than males (51.81±14.93 years, p<0.001). This study showed significant positive correlations between uric acid concentration, creatinine (r=0.201, p=0.018) and platelet count (r=0.169, p=0.046). The wild-type homozygous CYP2C9*1/*1 genotype was found in 92.09% of patients; the CYP2C9*1/*3 and CYP2C9*3/*3 genotypes were identified in 7.19% and 0.72%, respectively. No significant differences in most paraclinical parameters were observed between genotype groups, except for HDL-C levels, which were significantly higher in CYP2C9*3 carriers (p=0.000).
CONCLUSION: This study showed that the CYP2C9*3 carrier is significantly associated with higher HDL-C levels compared to the CYP2C9*1/*1 in gout patients. This finding suggests that the CYP2C9*3 variant may influence lipid metabolism in a way that promotes a more favorable lipid profile, which are considered protective against cardiovascular disease.
KEYWORDS: CYP2C9 gene, CYP2C9*3, CYP2C9 rs1057910 genotype, gout patients, paraclinical characteristics
Full Text:
PDFReferences
Richette P, Bardin T. Gout. Lancet. 2010; 375(9711): 318-28, CrossRef.
Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016; 388(10055): 2039-52, CrossRef.
Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective-A review. J Adv Res. 2017; 8(5): 495-511, CrossRef.
Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Re. 2012; 64(10): 1447-61, CrossRef.
Hoa TTM, Darmawan J, Le Chen S, Van Hung N, Nhi CT, An TN, et al. Prevalence of the rheumatic diseases in urban Vietnam: a WHO-ILAR COPCORD study. J Rheumatol. 2003; 30(10): 2252-56, PMID.
Hung PQ, Canh NX, Duong NT. Study on association between SLC2A9 rs3733591 and Gout susceptibility in 481 Vietnamese individuals. Viet J Sci Tech Eng. 2022; 64(1): 39-42, CrossRef.
Dean L, Kane M. Celecoxib therapy and CYP2C9 genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries. Bethesda: National Center for Biotechnology Information; 2021. p.141-50, PMID.
Dean L. Lesinurad Therapy and CYP2C9 genotype. In: Victoria M, Pratt SAS, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, et al, editors. Medical Genetics Summaries. Bethesda: National Center for Biotechnology Information; 2019. p.347-53.
Dean L, Kane M. Pegloticase therapy and G6PD genotype. In: Victoria M, Pratt SAS, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, et al, editors. Medical Genetics Summaries. Bethesda: National Center for Biotechnology Information; 2020. p.415-24, PMID.
Dean L, Kane M. Allopurinol therapy and HLA-B*58:01 genotype. In: Victoria M, Pratt SAS, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, et al, editors. Medical Genetics Summaries. Bethesda: National Center for Biotechnology Information; 2020. p.17-27, PMID.
Tjajaindra A, Sari AK, Simamora A, Timotius KH. The stem infusate and ethanol extract of physalis angulata inhibitory activities against a-glucosidase and xanthine oxidase. Mol Cell Biomed Sci. 2021; 5(3): 115-20, CrossRef.
Lee CR, Goldstein JA, Pieper JA. Cytochrome P4502C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics Genom. 2002; 12(3): 251-63, CrossRef.
Kim SH, Kim DH, Byeon JY, Kim YH, Kim DH, Lim HJ, et al. Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Arthrit Care Res. 2017; 40: 382-90, CrossRef.
Zhou Y, Nevosadová L, Eliasson E, Lauschke VMJHg. Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences. Hum Genomics. 2023; 17(1): 15, CrossRef.
Vu NP, Ma TTH, Tran NTB, Huynh HTT, Nguyen TD, Nguyen DT, et al. Polymorphic analysis of CYP2C9 gene in Vietnamese population. Mol Biol Reports. 2018; 45(5): 893-900, CrossRef.
Lee SS, Kim KM, Thi-Le H, Yea SS, Cha IJ, Shin JG. Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population. Ther Drug Monit. 2005; 27(2): 208-10, CrossRef.
UNFPA. Ethnics Groups in Viet Nam: An Analysis of Key indicators from the 2009 Viet Nam Population and Housing Census. Ha Noi: United Nations Population Fund in Viet Nam; 2011, article.
Jung E, Kong SY, Ro YS, Ryu HH, Shin SD. Serum cholesterol levels and risk of cardiovascular death: A systematic review and a dose-response meta-analysis of prospective cohort studies. Int J Environ Res Public Health. 2022; 19(14): 8272, CrossRef.
Zhao X, Wang D, Qin L. Lipid profile and prognosis in patients with coronary heart disease: A meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2021; 21(1): 69, CrossRef.
Luo CH, Wang A, Zhu RH, Zhang WX, Mo W, Yu BN, et al. Gender specific association of CYP2C9*3 with hyperlipidaemia in Chinese. Br J Clin Pharmacol. 2005; 60(6): 629-31 CrossRef.
Phabphal K, Geater A, Limapichart K, Sathirapanya P, Setthawatcharawanich S. Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients. J Seizure. 2013; 22(2): 103-08, CrossRef.
Ahmed JH, Makonnen E, Yimer G, Seifu D, Bekele A, Assefa M, et al. CYP2J2*7 genotype predicts risk of chemotherapy-induced hematologic toxicity and reduced relative dose intensity in Ethiopian breast cancer patients. Front Pharmacol. 2019: 10: 481, CrossRef.
Gremmel T, Kopp CW, Seidinger D, Koppensteiner R, Panzer S, Sunder-Plassmann R, et al. Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. Int J Cardiol. 2013; 166(1): 126-31, CrossRef.
Smith A, Baumgartner K, Bositis C. Cirrhosis: Diagnosis and management. Am Fam Physician. 2019; 100(12): 759-70, CrossRef.
Hoang YTT, Nguyen YT, Vu LT, Bui HTT, Nguyen QV, Vu NP, et al. Association of ADH1B rs1229984, ADH1C rs698, and ALDH2 rs671 with alcohol abuse and alcoholic cirrhosis in people living in Northeast Vietnam. Asian Pac J Cancer Prev. 2023; 24(6): 2073-82, CrossRef.
Hoang YTT, Nguyen YT, Nguyen HD, Le ATP, Bui HTT, Vu NP, et al. Single nucleotide polymorphisms of ADH1B, ADH1C and ALDH2 genes in 235 people living in thai nguyen province of Vietnam. Asian Pac J Cancer Prev. 2022; 23(12): 4243-51, CrossRef.
Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004; 350(11): 1093-103, CrossRef.
Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheumatism. 2011; 63(10): 3136-41, CrossRef.
Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: A retrospective cohort study in a large US managed care population. BMC musculoskeletal disorders. 2011; 12: 103, CrossRef.
Zheng X, Gong L, Luo R, Chen H, Peng B, Ren W, et al. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. Lipids Health Dis. 2017; 16(1): 202, CrossRef.
Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis. 2013; 231(1): 61-8, CrossRef.
Liang J, Jiang Y, Huang Y, Song W, Li X, Huang Y, et al. The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: A cross-sectional study. Lipids Health Dis. 2020; 19: 31, CrossRef.
Sargowo D, Handayani O. The association between cardiovascular risk and elevated triglycerides. Indones Biomed J. 2017; 9(1): 17-22, CrossRef.
Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013; 61(1): 134-46, CrossRef.
Malekmohammad K, Bezsonov EE, Rafieian-Kopaei M. Role of lipid accumulation and inflammation in atherosclerosis: focus on molecular and cellular mechanisms. Front Cardiovasc Med. 2021; 8: 707529, CrossRef.
Supriami K, Puspitawati I, Mayasari DS, Hartopo AB. Increased platelet-derived microparticles counts is correlated with elevated blood LDL cholesterol in acute myocardial infarction. Indones Biomed J. 2022; 14(3): 261-8, CrossRef.
Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthrit Care Res. 2007; 57(1): 109-15, CrossRef.
Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009; 41(2): 89-295, CrossRef.
Kaniawati M, Wijaya A, Susanto A. The correlations between concentrations of myeloperoxidase, serum amyloid-A protein and secretory phospolipase A-2 with proinflammatory HDL in healthy male person. Indones Biomed J. 2009; 1(1): 53-60, CrossRef.
Pirro M, Siepi D, Lupattelli G, Roscini AR, Schillaci G, Gemelli F, et al. Plasma C-reactive protein in subjects with hypo/hyperalphalipoproteinemias. Metabolism. 2003; 52(4): 432-36, CrossRef.
DOI: https://doi.org/10.18585/inabj.v17i4.3713
Copyright (c) 2025 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
